Patient-Derived Xenografts (PDX) for Drug Development
Mediford Corporation offers a variety of contract services from establishment and banking of PDX-derived cell lines to conducting pharmacological studies at the GLP-certified facilities of Kumamoto Laboratories. The PDX models are more predictive of clinical outcomes than conventional "cancer cell lines" and will be useful for your research and development purposes.
The PDX model (Patient-Derived Xenograft) is a mouse model in which patient-derived cancer tissue is transplanted into immunodeficient mice. PDX models are a mainstream modality in anticancer drug research and development as an innovative tool with high clinical predictive performance.
LSI Medience (as of 2020) has established a PDX library (J-PDX library) derived from Japanese cancer patients in collaboration with the National Cancer Center and the National Institutes of Biomedical Innovation, Health and Nutrition as a project under Cyclic Innovation for Clinical Empowerment (CiCLE) of the Japan Agency for Medical Research and Development.*1
Under the management of mediford, the J-PDX library and the infrastructure for utilizing PDX for drug development and cancer treatment have been established at Kumamoto Laboratories and various services using J-PDX are available.
For more information on the use of J-PDX, please refer to the introduction page* of the National Cancer Center.*2
The PDX library established by the Central Institute for Experimental Animals is also available.
We receive patient tissues from medical institutions, pharmaceutical companies, and academia, etc., and establish new PDX cell lines. We can also store the established PDX cell lines at the GLP-certified Kumamoto Laboratories.
Work flow from PDX establishment to preservation
TG1 mouse: First generation of transplantation
Target Confirmation Study
We perform various expression analysis of target molecules for drug discovery, etc. FFPE slides and tissue microarrays (FFPE) are available when using J-PDX.
Tissue array information
Tissue microarrays (TMA) are available for PDX of the following cancers.
We can analyze protein expression in multiple PDX-derived tissues simultaneously on a single slide.
These are available for target confirmation when selecting PDX.
Type of cancer
Number of PDXs
Number of TMA blocks
Lung cancer
12
2
Esophagus cancer
8
1
Stomach cancer
6
1
Colon cancer
27
5
Biliary cancer
7
1
Pancreatic cancer
8
2
Brain cancer
8
1
Breast cancer
12
2
Ovarian cancer
6
1
* To use all PDXs listed in the "Number of PDXs" column, it is necessary to use all blocks listed in the "Number of TMA Blocks" column.
Example of TMA staining
This is an example of staining of serial sections of TMA block with HE staining and HER2 staining.
HE stainingHER2 staining
* The same PDX may be mounted on multiple TMA blocks.
Confirmation of targets by immunostaining (representative examples)
Breast cancer PDX
HER2Lung cancer PDX
EGFRLung cancer PDX
ALK
PDX In Vivo Anti-tumor Study
Example of anti-tumor test using pancreatic cancer PDX
Other Related Studies
Various analyses related to studies using PDX are also available.
Gene expression analysis after anti-tumor studies
Gene expression analysis of PDX tumors is available at each point after start of drug administration or at the end of observation. RNA is extracted from the samples, followed by RNAseq, and then expression analysis after removal of mouse reads.
Drug concentration measurement
Drug concentrations are measured by collecting samples (blood, tumor tissue, etc.) at various points after start of drug administration.
Study Period
Standard study period
Target confirmation study by immunostaining
1 to 1.5 months
In vivo anti-tumor study
from 6 months to longer
Development of PDX-related Technology
PDX-3D Culture Model (contract service menus are coming soon)
We have newly developed 3D spheroid culture technology using PDX tumors for pancreatic, lung, colon, and gastric cancers (international patent pending).
PDX Library
We provide three libraries.
National Cancer Center:J-PDX® Library
We have established a PDX library (J-PDX library) derived from Japanese cancer patients in collaboration with the National Cancer Center and the National Institutes of Biomedical Innovation, Health and Nutrition as a project under Cyclic Innovation for Clinical Empowerment (CiCLE) of the Japan Agency for Medical Research and Development. J-PDX® is a registered trademark of the National Cancer Center in Japan.
Central Institute for Experimental Animals: CIEA-PDX® Library
Approximately 230 cell lines from the Central Institute for Experimental Animals' library are available. CIEA-PDX® is a registered trademark of the Central Institute for Experimental Animals in Japan.
Saitama Medical University International Medical Center
Gynecological cancer PDX, established jointly by Saitama Medical University International Medical Center and the National Cancer Center, is available. Please contact us for more details.
What is J-PDX Library?
J-PDX library is a PDX library derived from Japanese cancer patients which was established by LSI Medience (as of 2020) as part of the environmental development project "Project to Establish a PDX Library Derived from Japanese Cancer Patients for the Promotion of Cancer Treatment" under the "CiCLE" project for creating an innovative platform for medical research and development by the Japan Agency for Medical Research and Development (AMED). Tumor specimens are received from patients at the National Cancer Center, and PDX is produced at the National Cancer Center Research Institute, and then maintained and managed at our GLP-certified Kumamoto Laboratories.
J-PDX Library is an industrially available library, established with high reliability and strictly controlled in Japan to support the creation of breakthrough new drugs in Japan.
Features of J-PDX Library
Patient informed consent has been obtained, available for use in contract studies
Maintained and managed in dedicated PDX animal rooms at the GLP-certified facility of Kumamoto Laboratories
PDX produced in a number of cancer types, including rare cancers
Established with numerous specimens of relapse and drug-resistant phases have been established.
Clinical information is managed by the National Cancer Center
Gene mutation and gene expression information are available.
J-PDX Library Information
(Breakdown of 410 PDXs as of July 2021) *Please contact us for the latest information, establishment and availability are always changing.
Please contact us for gene expression information.
Immunodeficient Animals
We have several strains of immunodeficient mice available for PDX transplantation. We, in cooperation with the PDX cell line suppliers, ensure that ethical, legal, and social issues (ELSI), Cartagena Protocol, biosafety, and microbial control of pathogens are appropriately addressed.
